Results 101 to 110 of about 657,649 (153)

Design, synthesis and biological evaluation of pyrazolo[3,4-b]pyridine derivatives as TRK inhibitors. [PDF]

RSC Med Chem, 2023
Liu N, Wang X, Fu Q, Qin Q, Wu T, Lv R, Zhao D, Cheng M.   +7 more
europepmc   +1 more source

Secretory Breast Carcinoma in A Six-Year-Old Girl: Case Report With Genetic Insights and Therapeutic Implications

Balkan Journal of Medical Genetics
Secretory breast carcinoma (SBC) is an extremely rare subtype, accounting for ~1% of breast cancers but representing the most common malignant breast tumor in pediatric patients.
Vlahović A, Nikolić S, Djuričić S M, Dunđerović D, Ilić N, Sarajlija A, Denčić Fekete M, Cvetinović A, Vasić M   +8 more
doaj   +1 more source

TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer. [PDF]

J Cancer, 2021
Sohn SH, Sul HJ, Kim B, Kim BJ, Kim HS, Zang DY.   +5 more
europepmc   +1 more source

Abstract LB-118: Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation

, 2019
Background: TRK inhibition is now standard of care for advanced pediatric and adult patients (pts) with TRK fusion solid tumors, regardless of origin. To date, TRK kinase domain mutations are the only known resistance mechanism, and next-generation TRK ...
Toska, Eneda, Mattar, Marissa, Scaltriti, Maurizio, Marissa Mattar, Lanman, Richard B., Sophie Shifman, Tuch, Brian B., Kulick, Amanda, David M. Hyman, Ebata, Kevin, Samoila, Aliaksandra, Hyman, David M., Somwar, Romel, Shifman, Sophie, Sean Guzman, Nagy, Rebecca J., Rebecca J. Nagy, Emiliano Cocco, Helen H. Won, S Duygu Selçuklu, Yaeger, Rona, Eneda Toska, Hechtman, Jaclyn F., Michael F. Berger, Jaclyn F. Hechtman, Richard B. Lanman, Marc Ladanyi, Sandra Misale, Rona Yaeger, Aliaksandra Samoila, Schram, Alison M., Amanda Kulick, Romel Somwar, Kevin Ebata, Alexander Drilon, Brian B. Tuch, Alison M. Schram, Stanchina, Elisa de, Cownie, James, Berger, Michael F., Drilon, Alexander, Misale, Sandra, Ryan Ptashkin, James Cownie, Razavi, Pedram, Ladanyi, Marc, Maurizio Scaltriti, Won, Helen H., Cocco, Emiliano, Ptashkin, Ryan, Guzman, Sean, Selçuklu, S Duygu, Pedram Razavi, Elisa de Stanchina   +53 more
core   +1 more source

Sustained response to larotrectinib in a pediatric patient with recurrent STRN3::NTRK2 fusion-positive pilocytic astrocytoma

CNS Oncology
A 7-year-old female with recurrent midline pilocytic astrocytoma harboring a rare STRN3::NTRK2 fusion achieved sustained near-complete radiographic and clinical response to larotrectinib, a selective TRK inhibitor.
Kishore Balasubramanian, Kar-Ming Fung, Rene Y. McNall-Knapp, Karl Balsara   +3 more
doaj   +1 more source

Erratum: Author correction to "Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers" [Acta Pharmaceutica Sinica B 11 (2021) 355-372]. [PDF]

Acta Pharm Sin B, 2022
Jiang T, Wang G, Liu Y, Feng L, Wang M, Liu J, Chen Y, Ouyang L.   +7 more
europepmc   +1 more source

ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models

Cell Reports
Summary: Pediatric-type high-grade gliomas frequently harbor gene fusions involving receptor tyrosine kinase genes, including neurotrophic tyrosine kinase receptor (NTRK) fusions.
Sebastian Schmid, Zachary R. Russell, Alex Shimura Yamashita, Madeline E. West, Abigail G. Parrish, Julia Walker, Dmytro Rudoy, James Z. Yan, David C. Quist, Betemariyam N. Gessesse, Neriah Alvinez, Kimberly D. Hill, Larry W. Anderson, Patrick J. Cimino, Debra K. Kumasaka, Ralph E. Parchment, Eric C. Holland, Frank Szulzewsky   +17 more
doaj   +1 more source

Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors. [PDF]

PLoS One, 2022
Hibar DP, Demetri GD, Peters S, Davies J, Humblet O, Maund SL, Perez L.   +6 more
europepmc   +1 more source

STAT3 activation by TRK oncogenes.

, 2013
(A) Western blot analysis of PC12 cells transfected with empty pRC/CMV vector, TRKA, TRK-T3, and TRK cDNAs. NGF treatment (50ng/ml, 10′) is indicated. Cell lysates and immunocomplexes were separated by SDS PAGE as described in Material and Methods and ...
Angela Greco (241294), Tiziana Fumagalli (366625), Maria Chiara Anania (366626), Sonia Pagliardini (366629), Claudia Miranda (241297), Maria Grazia Vizioli (366627), Marco A. Pierotti (241299)   +6 more
core   +1 more source

Syntheses and Evaluation of Carbon-11- and Fluorine-18-Radiolabeled pan-Tropomyosin Receptor Kinase (Trk) Inhibitors: Exploration of the 4‑Aza-2-oxindole Scaffold as Trk PET Imaging Agents

, 2016
Tropomyosin receptor kinases (TrkA/B/C) are critically involved in the development of the nervous system, in neurological disorders as well as in multiple neoplasms of both neural and non-neural origins.
Alexey Kostikov (1653292), Pedro Rosa-Neto (301841), Robert Hopewell (1653301), Alexander Thiel (1653298), Mehdi Boudjemeline (1653295), Antonio Aliaga (1653307), Vadim Bernard-Gauthier (1653289), Arturo Aliaga (1653304), Ralf Schirrmacher (1653310)   +8 more
core   +1 more source